Odronextamab is a stable humanized IgG4 CD20 * CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research[1].
Molecular Weight:
(144 kDa)
Purity:
99.50
CAS Number:
[1801338-64-6]
Target:
CD20,CD3
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted